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Abstract
Background Treatment of soft tissue sarcoma (STS)
includes complete tumor excision. However, in some
patients, residual sarcoma cells remain in the tumor bed.
We previously described a novel hand-held imaging device
prototype that uses molecular imaging to detect micro-
scopic residual cancer in mice during surgery.
Questions/purposes To test this device in a clinical
trial of dogs with naturally occurring sarcomas, we asked:
(1) Are any adverse clinical or laboratory effects observed
after intravenous administration of the fluorescent probes?
(2) Do canine sarcomas exhibit fluorescence after admin-
istration of the cathepsin-activated probe? (3) Is the tumor-
to-background ratio sufficient to distinguish tumor from
tumor bed? And (4) can residual fluorescence be detected
in the tumor bed during surgery and does this correlate with
a positive margin?
Methods We studied nine dogs undergoing treatment for
10 STS or mast cell tumors. Dogs received an intravenous
injection of VM249, a fluorescent probe that becomes
optically active in the presence of cathepsin proteases.
After injection, tumors were removed by wide resection.
The tumor bed was imaged using the novel imaging device
to search for residual fluorescence. We determined corre-
lations between tissue fluorescence and histopathology,
cathepsin protease expression, and development of recur-
rent disease. Minimum followup was 9 months (mean,
12 months; range, 9–15 months).
Results Fluorescence was apparent from all 10 tumors
and ranged from 3 9 107 to 1 9 109 counts/millisecond/
cm2. During intraoperative imaging, normal skeletal mus-
cle showed no residual fluorescence. Histopathologic
assessment of surgical margins correlated with intraoper-
ative imaging in nine of 10 cases; in the other case, there
was no residual fluorescence, but tumor was found at the
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margin on histologic examination. No animals had recur-
rent disease at 9 to 15 months.
Conclusions These initial findings suggest this imaging
system might be useful to intraoperatively detect residual
tumor after wide resections.
Clinical Relevance The ability to assess the tumor bed
intraoperatively for residual disease has the potential to
improve local control.
Introduction
Current treatment for soft tissue sarcoma (STS) includes
complete excision of the tumor with a surrounding margin
of normal tissue such that no malignant cells remain in the
tumor bed. The presence of residual sarcoma cells in the
tumor bed is associated with local recurrence and
decreased disease-specific survival [10, 15, 17, 18]. At
present, surgical margin status is determined by the eval-
uation of the resected specimen by a pathologist. A
comprehensive assessment of surgical margins requires
days to weeks to complete and, for large STSs, is prone to
sampling error [17]. For patients with tumor cells present at
the margin of the resected specimen, additional therapy is
required to achieve local control. This may include repeat
surgical resection and/or adjuvant radiation therapy with its
attendant increase in patient morbidity and healthcare
costs.
These factors have led to great interest in approaches
that allow surgical margin assessment at the time of the
initial resection. Available approaches for intraoperative
margin assessment using ultrasound [6], radiofrequency
spectroscopy [1], and frozen sections [14] have limitations.
Intraoperative ultrasound has little capacity for magnifi-
cation and is not likely to detect small residual collections
of tumor. Radiofrequency spectroscopy is technically
complex and not readily adaptable to the live operative
setting. Frozen sections are time consuming and are subject
to sampling error, especially in the large tumor beds
associated with sarcoma resection.
To address this unmet clinical need for real-time,
intraoperative assessment of microscopic residual sarcoma
in the tumor bed, we collaborated with engineers from
Massachusetts Institute of Technology (Cambridge, MA,
USA) to develop a novel, wide-field-of-view imaging
system that, when coupled with a near-infrared (NIR)
fluorescent probe, can resolve microscopic clusters of
tumor cells [12]. The NIR probe becomes optically active
when cleaved by cathepsin proteases. We have demon-
strated, in a genetically engineered mouse model of STS
[13], these NIR probes are selectively activated in sarco-
mas because cathepsin proteases are overexpressed in STSs
in mice [8, 12]. We used the system in mice with geneti-
cally engineered STSs to detect residual NIR fluorescence
within the tumor bed [12]. The mice underwent
intralesional, marginal, and wide resection of their tumors.
Intraoperative fluorescent imaging results were correlated
with histopathology and the mice were followed clinically
for local recurrence. The presence of residual fluorescence
correlated with local recurrence, and resection of this
residual NIR fluorescence improved local control. Despite
the ability to image residual tumor in mice, it is unclear
whether this technology can be successfully translated into
the clinic where spontaneous tumors arise from a more
diverse set of initiating gene mutations, which might affect
cathepsin protease expression [2]. In addition, because the
mouse sarcomas are relatively small (approximately
1–2 cm), results of surgical studies in mice may not fully
translate to surgery in patients with large sarcomas
(5–15 cm).
Sarcomas occur much more commonly in dogs,
accounting for 15% of all tumors [5]. The primary therapy
for canine STS, as in humans, is resection of the tumor with
negative surgical margins [5]. Therefore, to test this
imaging system in spontaneous tumors in a clinical setting,
we initiated a canine clinical trial.
In this clinical trial in dogs with naturally occurring
sarcomas, we answered the following questions: (1) Are
any adverse clinical or laboratory effects observed after
intravenous administration of the fluorescent probes to
dogs undergoing resection of sarcomas? (2) Do naturally
occurring canine sarcomas exhibit fluorescence after
administration of the cathepsin-activated probes? (3) If so,
is the tumor-to-background ratio sufficient to distinguish
tumor from normal tumor bed during resection of naturally
occurring canine tumors? And (4) can residual NIR fluo-
rescence be detected in the tumor bed in the live operative
setting and does this correlate with a positive margin of the
resected tumor?
Materials and Methods
Between November 2010 and May 2011, we treated a total
of 30 dogs for tumors identified by biopsy as either STS or
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canine mast cell tumor (MCT) (a malignancy of soft tis-
sues, which is similar to STS). Each dog presented to the
Veterinary Specialty Hospital of the Carolinas for treat-
ment by a multidisciplinary small-animal oncology team.
Five dogs had underlying organ dysfunction (four with
chronic renal insufficiency, one with hepatic insufficiency)
and their owners were not offered enrollment. We offered
enrollment to the owners of the remaining 25 dogs, but 14
declined to participate, leaving 11 dogs (12 tumors) for
potential participation in the study. Of the 12 tumors, two
tumors (two dogs) were found not to have sarcomas based
on final histopathology. One dog had a history of previous
incomplete excision of a STS on the ventral chest wall.
Repeat excision of the tumor bed revealed no residual
tumor on gross or microscopic evaluation. One dog with a
periumbilical mass believed to be STS based on core
needle biopsy showed necrosis, fibrosis, and chronic
inflammation but no identifiable neoplasia. These two dogs
were excluded from analysis, leaving 10 tumors in nine
dogs for analysis (Table 1). There were five males and four
females. No single breed was represented more than twice.
Mean age was 9.5 years (range, 5–12 years). Mean body
weight was 25 kg (range, 7.9–39.1 kg). Minimum fol-
lowup was 10 months (mean, 13 months; range, 9–
16 months). No dog was lost during the period of followup.
Histopathologic diagnoses included six STSs in five dogs
and MCTs in four dogs. We had prior approval from the
Duke University Institutional Animal Care and Use Com-
mittee (Duke IACUC Protocol A213-10-08).
As shown in the optical layout of the imaging device
(Fig. 1A), the device employs white light illumination for
excitation and a set of spectral filters (excitation filter,
dichroic mirror, and emission filter) for fluorescence
imaging. Several lenses are used to relay the fluorescence
image at no magnification into a charge-coupled device
where the fluorescence emission of individual cancer cells
is mapped into 2 to 4 pixels. The device was essentially
similar to that previously reported [12] but was subse-
quently modified in several important ways to facilitate its
use in the operating room. First, the bench-mounted pro-
totype was adapted for use on a rolling platform that could
be brought to adjustable proximity and location relative to
the operating table. Second, because the original surgeries
in mice were semisterile, the device was adapted for sterile
use. Sterilizable sleeves and a sterilizable objective lens
cover were custom-made so that the device could be used
in a fully sterile fashion. The computer display was adapted
for use on a rolling platform so that it could be readily seen
by the surgeon. Additionally, the display was modified so
that fluorescence above the desired threshold would be
displayed in red on the visual display to allow for rapid
detection of residual fluorescence.
After obtaining informed consent from the owners, the
dogs were given a dose of the cathepsin-activated NIR
imaging probe VM249 (Visen Medical/Perkin Elmer,
Waltham, MA, USA; dose range, 0.5–2 mg/kg) by intra-
venous injection. Dogs were kept in the intensive care unit
after injection of the probe and for 24 hours after surgery to
monitor for adverse effects, namely anaphylaxis, injection
site inflammation, or behavioral changes. In all dogs, a
baseline preoperative CBC and serum biochemistry profile
had been obtained. In six dogs, a postoperative CBC and
serum biochemistry profile were obtained on Postoperative
Day 1. In five dogs, these tests were declined by the owners
due to cost concerns. The first two dogs had surgery
6 hours after injection as this time point had worked in the











1 6.8 19.8 Brittany MPNST Negative Negative No
2 7 20 Australian cattle dog UPS Negative Negative No
3 9.9 30.1 Labrador MPNST Negative Negative No
4 6.6 34.3 Mixed breed MCT Positive Positive No
5 6 22.3 Bassett hound MCT Negative Negative No
6 9.3 39.1 Labrador MPNST Negative Positive No
7 5 37.6 Mixed breed MCT Negative Negative No
8 11 14.4 Bassett hound MCT Negative Negative No
9* 12 7.9 Schnauzer Fibrosarcoma Negative Negative No
9* 12 7.9 Schnauzer MPNST Negative Negative No
* Dog 9 had two different sarcomas; visually detectable fluorescence was calibrated based on imaging of a cut surface of the resected tumor; an
intensity threshold to image residual fluorescence was set based on 80% of the minimum fluorescence emission rate from each tumor; pixels from
the tumor bed image with emission rates at or above the threshold were identified in real time using an automatic software routine;
MPNST = malignant peripheral nerve sheath tumor; UPS = undifferentiated pleomorphic sarcoma; MCT = mast cell tumor.
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mouse studies [12]. To account for potential differences in
pharmacokinetic parameters between mice and dogs, the
remaining dogs were imaged at 24 hours after injection.
Standard wide or radical resection of the tumor was per-
formed by a board-certified veterinary surgeon (CAE). The
resected specimen was removed from the operative field
and incised to expose the tumor. The exposed portion of
the tumor was imaged with the device and pixel intensity
values were normalized by exposure time to obtain a time-
independent fluorescence emission rate. Based on our
previous experience in mice [12], an intensity threshold to
image residual NIR fluorescence was set based on 80% of
the minimum fluorescence emission rate from each tumor.
Resected tumors were then inked and transported to the
histopathology laboratory.
After setting the threshold, the imaging device was
covered with a sterile sleeve and brought into the operative
field. The operating surgeon used the device to scan the
entire tumor bed (specifically all exposed tissue) (Fig. 1B).
Because this technology is investigational, we did not have
approval to modify the operative plan (ie, resect more
tissue) based on imaging results. The time required to
image the tumor and the tumor bed was approximately
15 minutes/tumor. Pixels from the tumor bed image with
emission rates at or above the threshold were identified in
real time using an automatic software routine [12]. After
surgery, three of us (JKM, JEC, JMF) also analyzed images
obtained at the time of surgery to ensure correct intraop-
erative assessment. The tumor bed was classified as having
either positive or negative residual fluorescence based on
the threshold calibration. The wound was irrigated and
closed. Postoperative care was routine and was not affected
by enrollment in this study. Biopsies of the resected tumor
and tumor bed were submitted to two different veterinary
pathologists for histopathologic analysis and comparison
with imaging results.
To determine whether positive fluorescence correlated
with the presence of cathepsin proteases within tumors
(and the absence of cathepsin proteases within surrounding
muscle), muscle-normalized transcription of RNA for
cathepsins B, K, L, and S (each of which cleave VM249)
was quantitatively measured via real-time PCR using the
iTaqTM SYBR1 Green supermix (Bio-rad Laboratories,
Inc, Hercules, CA, USA) with the following primers:
cathepsin B: 50-TGCGGTTCCTGCTGGGCATTT-30 and
50-TGACGTGCCCATTGGTGCGG-30; cathepsin L: 5-TT
GGAAGGGACACAGAGACCTGCA-30 and 50-GGGCCT
TCTCCCGTTGAGGGAG-30; cathepsin K: 50-ACCAGG
GTCAGTGTGGTTCCTGTT-30 and 50-GATGGGTCCCA
CTCGGGCCA-30; and cathepsin S: 50-TTGGGCTGCTTC
Fig. 1A–B (A) A diagram illustrates the optical layout of the
intraoperative imaging device. Light enters the device through the
fiber bundle where it is reflected through an excitation filter (ex filter)
and reflected with a dichroic mirror (DM) onto the tumor sample/
tumor bed where emitted light returns through the emission filter (em
filter) to the detector. Several lenses (L) are used to relay the
fluorescence image at no magnification into a charge-coupled device
(CCD) where the fluorescence emission of individual cancer cells is
mapped into 2 to 4 pixels. (B) A photograph shows the device in use
in a dog with a chest wall STS.
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CGTTGTGCTC-30 and 50-ACGCCGTGCTACTTCCTCA
TTCTCT-30; values were normalized to b2 M and RPS5
expression as described previously [4].
The closest surgical margin was determined by a single
veterinary pathologist (SE) after gross examination of the
specimen. The entire external surface of the specimen was
then inked and the specimen was cut perpendicularly to the
inked margin. Under microscopic examination, the dis-
tance between the tumor and the inked margin was
measured, using sections selected by the pathologist. Fro-
zen sections of both tumor and muscle (when available)
within the tumor bed were evaluated. We used the analysis
of frozen sections to guide microdissection of the tissues
for isolation of RNA using the Ambion1 RNAqueous1
microkit (Life Technologies, Burlington, ON, Canada).
Samples were included in this analysis if high-quality
RNA tumor and normal muscle could be isolated (A260/
280 C 1.8). Because we were not able to isolate normal
muscle from every dog and because in six samples (either
tumor or matched normal muscle from the tumor bed) the
RNA was not of sufficient quality, quantitative measure-
ment of the expression of cathepsin proteases in tumors and
matched normal muscle was performed in four dogs. Two
of us (JKM, JEC) independently assessed all sections for
cathepsin expression. For comparison, gene expression
data from previously reported canine studies were down-
loaded from Gene Expression Omnibus [3, 11] and
imported into GenePattern [16]. Data sets were combined
using ComBat [7]. Multiple probes mapping to a single
cathepsin were averaged together for the purposes of
generating a heat map. Hierarchical clustering was per-
formed using Pearson correlation row normalization.
Results
We identified no adverse reactions associated with
administration of the probe. One dog developed a postop-
erative wound infection, which was successfully treated
with de´bridement and antibiotics. In the six dogs where
postoperative CBC and serum biochemistry profiles were
available, there were no changes from baseline other than
anemia consistent with operative blood loss in one dog.
The cathepsin-activated NIR probe was activated by all
sarcomas. During imaging of the sectioned surface of
resected tumors on the back table, fluorescence ranging
from 3 9 107 to 1 9 109 counts/millisecond/cm2 was
apparent within all 10 tumors.
During intraoperative imaging of the tumor bed, no
residual fluorescence above the threshold was detected
Fig. 2A–F Representative intraoperative imaging of the dogs is
shown. Most of the dogs showed increased NIR fluorescence from
tumor compared to images from the tumor bed. (A) An image-
normalized intensity histogram shows distinct separation between
(B) tumor and (C) tumor bed images. In contrast, in Dog 4 with an
MCT, (D) an image-normalized intensity histogram shows a separa-
tion between (E) tumor and (F) tumor bed that is not as distinct; (F) a
small area of residual fluorescence (arrow) was detected in the tumor
bed after resection that was greater than the threshold of 80% of the
minimum signal from the tumor.
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(Fig. 2A–C), except in one dog (Fig. 2D–F) (discussed
below). In the rest of the dogs, quantitative analysis of
fluorescence emission histograms showed no overlap
between the emission rates for the primary tumor (Fig. 2B)
and tumor bed (Fig. 2C). In the four dogs where quanti-
tative assessment of the expression of cathepsin proteases
was possible, expression of cathepsin proteases B (Fig. 3A),
K (Fig. 3B), L (Fig. 3C), and S (Fig. 3D) was greater in
tumor than in muscle from the tumor bed. Analysis of
previously reported canine gene expression data [11, 19]
showed overexpression of many cathepsin proteases in
canine STSs compared to normal skeletal muscle (Fig. 3E).
Histopathologic assessment of surgical margins corre-
lated with intraoperative imaging in nine of 10 tumors
(Table 1). For eight tumors, intraoperative assessment of
the tumor bed showed no residual fluorescence after
resection, and correlative histopathologic examination of
the resected tumors showed no extension of tumor to the
inked margins. For one tumor, a Grade II MCT in Dog 4,
intraoperative assessment of the tumor bed showed a focal
area of residual fluorescence (Fig. 2D–F), and correlative
histopathologic examination of the tumor showed a focal
area of tumor extension to the inked margin. Adjuvant
chemotherapy was given. Additional surgical resection was
not performed. This dog has no evidence of recurrent dis-
ease at 10 months after surgery. Histopathologic
assessment of surgical margins did not correlate with
intraoperative imaging in one case. One dog with a Grade
II malignant peripheral nerve sheath tumor (Dog 6) had no
residual fluorescence within the tumor bed, but histopath-
ologic assessment of the resected tumor showed a focal
area of tumor extension to the inked margin. Post hoc
review of the intraoperative images also revealed no
residual fluorescence within the tumor bed. This dog did
not receive additional resection or adjuvant therapy and has
no evidence of recurrent disease at 11 months after sur-
gery. At the time of this analysis, no dog in the study has
developed recurrent disease.
Discussion
We developed an imaging system that can distinguish
between normal tissue and cancer during oncologic resec-
tions. We previously demonstrated its efficacy in
identifying and directing resection of microscopic residual
sarcoma in a genetically engineered mouse model. To
translate this technology toward clinical use, several criti-
cal questions that cannot be answered in a laboratory
setting with a mouse model must be addressed. Therefore,
we addressed the following questions: (1) Are any adverse
clinical or laboratory effects observed after intravenous
administration of the fluorescent probes to dogs undergoing
resection of sarcomas? (2) Do naturally occurring canine
sarcomas exhibit fluorescence after administration of the
cathepsin-activated probes? (3) If so, is the tumor-to-
background ratio sufficient to distinguish tumor from tumor
bed during resection of naturally occurring canine tumors?
And (4) can residual NIR fluorescence be detected in the
tumor bed during surgery and does this correlate with a
positive margin of the resected tumor?
Our study has some limitations. First, this clinical trial
included a small number of dogs. Adverse effects of the
probe or practical limitations of the imaging system may
become apparent only after use in many individuals. Sec-
ond, we had a relatively short followup to assess local
recurrence. At the time of this analysis, no dog had recurrent
disease. Given a local recurrence rate of 15% in dogs with
STS [9], to evaluate the clinical performance of this
imaging system with enough events related to recurrent
disease, it will be necessary to include other veterinary
hospitals to accrue sufficient dogs. Third, in one dog, we
saw residual fluorescence, but we did not resect that area
and therefore could not confirm by histology that the
presence of residual fluorescence identified residual cancer
within the tumor bed. Future studies will therefore utilize
the imaging system to guide resection of the residual fluo-
rescence so confirmatory histologic analyses can be
performed. Fourth, the depth of visibility of fluorescent
tissue with this system is not yet known. It is possible tumor
cells deep to the exposed tumor bed are not detected
because their fluorescence does not penetrate the normal
tissue layer between the tumor cells and the imaging device.
We identified no obvious adverse clinical or laboratory
effects from the NIR imaging probe VM249 when injected
intravenously into the dogs at doses ranging from 0.5 to
2 mg/kg.
The cathepsin-activated NIR probe was activated by
spontaneous naturally occurring canine sarcomas. In con-
trast to mice, the signal in the canine tumors exhibited a
wider range of fluorescence emission (3 9 107 to 1 9
109 counts/millisecond/cm2) consistent with a variety of
disease sites and tumor types imaged. Just as we observed
increased expression of cathepsin proteases in primary
mouse sarcomas compared to normal muscle [12], we also
observed increased expression of cathepsin proteases in
naturally occurring canine sarcomas (Fig. 3). Interestingly,
in tumor samples with available matched normal muscle
and with RNA of sufficient quality for analysis, different
sarcomas expressed different levels of cathepsin proteases.
For example, the sarcoma in Dog 2 expressed relatively
higher levels of cathepsins B and L, while the sarcoma in
Dog 9 preferentially expressed cathepsins S and K. This
suggests an NIR imaging probe such as VM249 that is
activated by multiple cathepsin proteases may be most
useful to image heterogeneous STSs. Nevertheless, our
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Fig. 3A–E Multiple cathepsin prote-
ases that activate VM249 are upregu-
lated in tumors compared to normal
muscle as detected by quantitative real-
time PCR: (A) cathepsin B, (B) cathepsin
K, (C) cathepsin L, and (D) cathepsin S.
(E) A heat map for a variety of cathepsins
in canine STS and skeletal muscle is
shown. Red indicates high levels of
cathepsin expression whereas blue indi-
cates low levels of cathepsin expression.
CTSD = cathepsin D, CTSF = cathep-
sin F, etc.
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observation that all tumors (n = 6 STSs and n = 4 MCTs)
tested so far activated VM249 suggests most canine STSs
express cathepsin proteases and indicates naturally occur-
ring canine sarcomas exhibit fluorescence after adminis-
tration of cathepsin-activated probes.
We found no residual fluorescence in nine tumor beds.
Therefore, there is sufficient tumor-to-background signal
ratio between sarcoma and adjacent normal tissue for this
imaging system to distinguish tumor from tumor bed dur-
ing surgery of naturally occurring canine sarcomas.
In one tumor bed (Dog 4), we detected a focus of
residual NIR fluorescence above the threshold to score as
positive residual fluorescence (Fig. 2, Table 1). This was
one of two tumors the veterinary pathologist identified as
having a positive margin. Therefore, in this tumor bed,
positive residual fluorescence correlated with positive
surgical margins on the excised tumor. In this dog, resec-
tion of this area of residual fluorescence might have been
useful but was not permitted by our animal use protocol as
this technology remained unproven in dogs, so modifica-
tion of the surgeon’s operative plan based on data from the
device was prohibited. Future studies will allow such
directed resection, which is, after all, the purpose of the
technology. However, this dog was treated with systemic
chemotherapy and remains disease free 10 months after
surgery.
In Dog 6, a resected sarcoma was identified as having a
focal positive margin, but in this case no residual NIR was
observed in the tumor bed. It is possible, although the
excised tumor had a focally positive margin, microscopic
residual sarcoma was not present in the tumor bed. Con-
sistent with this possibility, Dog 6 remains disease free
11 months after surgery even though this dog was not
treated with adjuvant therapy. Alternatively, it is possible
the positive surgical margin reflects a false-negative result
of the imaging system, which could be due to a suboptimal
dose of the probe, timing of probe administration relative
to surgery, or detection threshold.
Our findings allow us to make several conclusions.
Naturally occurring canine sarcomas express cathepsin
proteases and activate the NIR imaging probe VM249. In
addition, this imaging probe can be injected into dogs
undergoing surgery without detectable adverse events.
Moreover, the tumor-to-background signal ratio indicates
this imaging system can discriminate tumor from adja-
cent normal tissue. Further clinical followup will be
needed to correlate the imaging results with the devel-
opment of recurrent disease. These initial results provide
a proof of concept of this imaging system in an early
phase trial in spontaneous sarcomas in dogs. Together
with our data in primary sarcomas in mice [12], this
study in dogs will serve as a precursor to clinical trials
in humans with sarcoma.
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